Xeno Biosciences Starts Phase 1b Proof-of-Concept Study in Obesity
June 25 2024 - 4:34PM
Business Wire
Xeno Biosciences Inc., a clinical stage drug discovery and
development company advancing therapeutics for the treatment of
obesity and metabolic diseases, announced today initiation of Phase
1b clinical study which is designed to provide proof-of-concept
weight loss results, along with safety and tolerability, using an
optimized formulation of the drug candidate XEN-101, in obese
adults. The trial is expected to have top line results by the end
of the year.
The Phase 1b study is a double blinded, randomized, placebo
controlled, parallel group design testing multiple doses of Xen-101
vs. placebo over 4-week period in 32 adults with BMI between 30 and
45 kg/m2. The study is being conducted in Australia and safety,
tolerability, and total body weight change at the 4-week endpoint
will be the primary objectives. Pharmacodynamic effects, including
microbiome composition, serum ketone levels, metabolic biomarkers,
and changes in self-reported appetite and hunger will also be
investigated.
“We’re confident that this study design will deliver proof-of
concept body weight reduction results after 4-weeks of therapy in
the background of already documented excellent safety and
tolerability profile,” said Dr. Dennis Kim, President and CEO of
Xeno Biosciences. “With a daily oral administration schedule and a
novel and differentiated mechanism of action, we believe Xeno is
well-positioned to demonstrate Xen-101 as a new, exciting, and
sought-after drug candidate that can address the strong and
remaining unmet needs in the obesity field.” The results of the
Phase 1b study are expected by the end of 2024.
For more information about Xeno Biosciences please contact Dr.
Dennis Kim at dk23@xenobiosciences.com.
About Xeno Biosciences Inc.
Xeno Biosciences Inc. is a privately held drug development company
dedicated to finding safe and effective treatments for obesity and
metabolic diseases. Xeno is advancing its lead development
candidate, XEN-101, to address the unmet need for an effective,
well-tolerated, orally administered obesity treatment. With a new
understanding of the underlying mechanism of action of Roux-en-Y
Gastric Bypass Surgery (RYGB), Xeno has developed a substitute for
gastric bypass in a daily oral pill. XEN-101 has been shown to have
wide safety margins and high tolerability in initial clinical
trials.
The securities sold in the aforementioned private placement have
not been registered under the Securities Act of 1933, as amended,
and may not be offered or sold in the United States in the absence
of an effective registration statement or an applicable exemption
from the registration requirements of the Securities Act. This
press release shall not constitute an offer to sell or the
solicitation of an offer to buy the aforementioned shares. In
addition, this press release contains certain forward-looking
statements regarding, among other things, statements relating to
goals, plans and projections regarding the company’s financial
position, results of operations, market position, product
development and business strategy. Such forward-looking statements
are based on current expectations and involve inherent risks and
uncertainties, including factors that could delay, divert or change
any of them, and could cause actual outcomes and results to differ
materially from current expectations. No forward-looking statements
can be guaranteed and actual results may differ materially from
such statements. The information in this release is provided only
as of the date of this release, and the company undertakes no
obligation to update any forward-looking statements contained in
this release on account of new information, future events, or
otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240625622967/en/
For more information about Xeno Biosciences please contact Dr.
Dennis Kim at dk23@xenobiosciences.com.